Bebetter Med, Inc. Class ASSE: 688759

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for Iprinosine Hydrochloride for Injection (BEBT-908) Combined with CHOP in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

· Issued by Bebetter Med, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval Notification for Iprinosine Hydrochloride for Injection (BEBT-908) Combined with CHOP in the Treatment of Newly Diagnosed Peripheral T-Cell Lymphoma

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis

Earlier from Bebetter Med, Inc. Class A

All Bebetter Med, Inc. Class A news releases